|
MechanismCLDN18.2 modulators |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Qiagen (Suzhou) Translational Medicine Research Co., Ltd.
0 Patents (Medical) associated with Qiagen (Suzhou) Translational Medicine Research Co., Ltd.
100 Deals associated with Qiagen (Suzhou) Translational Medicine Research Co., Ltd.
100 Translational Medicine associated with Qiagen (Suzhou) Translational Medicine Research Co., Ltd.